TECH vs. NBIX, QGEN, RGEN, CRSP, DNLI, A, MTD, WAT, ILMN, and CRL
Should you be buying Bio-Techne stock or one of its competitors? The main competitors of Bio-Techne include Neurocrine Biosciences (NBIX), Qiagen (QGEN), Repligen (RGEN), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Illumina (ILMN), and Charles River Laboratories International (CRL).
Bio-Techne (NASDAQ:TECH) and Neurocrine Biosciences (NASDAQ:NBIX) are both large-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, community ranking, dividends and analyst recommendations.
In the previous week, Neurocrine Biosciences had 12 more articles in the media than Bio-Techne. MarketBeat recorded 22 mentions for Neurocrine Biosciences and 10 mentions for Bio-Techne. Bio-Techne's average media sentiment score of 0.85 beat Neurocrine Biosciences' score of 0.58 indicating that Bio-Techne is being referred to more favorably in the media.
Bio-Techne has higher earnings, but lower revenue than Neurocrine Biosciences. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.
Neurocrine Biosciences received 597 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.62% of users gave Neurocrine Biosciences an outperform vote while only 62.38% of users gave Bio-Techne an outperform vote.
Neurocrine Biosciences has a net margin of 18.65% compared to Bio-Techne's net margin of 17.59%. Neurocrine Biosciences' return on equity of 17.45% beat Bio-Techne's return on equity.
Bio-Techne currently has a consensus target price of $81.00, indicating a potential upside of 4.94%. Neurocrine Biosciences has a consensus target price of $150.85, indicating a potential upside of 11.40%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, analysts clearly believe Neurocrine Biosciences is more favorable than Bio-Techne.
Bio-Techne has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, Neurocrine Biosciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500.
98.9% of Bio-Techne shares are held by institutional investors. Comparatively, 92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.5% of Bio-Techne shares are held by insiders. Comparatively, 4.3% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Neurocrine Biosciences beats Bio-Techne on 12 of the 19 factors compared between the two stocks.
Get Bio-Techne News Delivered to You Automatically
Sign up to receive the latest news and ratings for TECH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TECH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bio-Techne Competitors List
Related Companies and Tools
